Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease
(2017) In Biology of Blood and Marrow Transplantation 23(1). p.172-175- Abstract
Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7f11bab7-3356-4615-82e4-48cb033ebcc8
- author
- Fløisand, Yngvar ; Lundin, Knut E A ; Lazarevic, Vladimir LU ; Kristiansen, Jørn Dehli ; Osnes, Liv T N ; Tjønnfjord, Geir E. ; Reims, Henrik Mikael and Gedde-Dahl, Tobias
- publishing date
- 2017-01-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Graft-versus-host disease, Gut GVHD, Integrin, Stem cell transplant, Steroid refractory, Vedolizumab
- in
- Biology of Blood and Marrow Transplantation
- volume
- 23
- issue
- 1
- pages
- 4 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85006351875
- pmid:27777142
- ISSN
- 1083-8791
- DOI
- 10.1016/j.bbmt.2016.10.009
- language
- English
- LU publication?
- no
- id
- 7f11bab7-3356-4615-82e4-48cb033ebcc8
- date added to LUP
- 2017-01-16 09:57:02
- date last changed
- 2024-09-22 06:13:43
@article{7f11bab7-3356-4615-82e4-48cb033ebcc8, abstract = {{<p>Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.</p>}}, author = {{Fløisand, Yngvar and Lundin, Knut E A and Lazarevic, Vladimir and Kristiansen, Jørn Dehli and Osnes, Liv T N and Tjønnfjord, Geir E. and Reims, Henrik Mikael and Gedde-Dahl, Tobias}}, issn = {{1083-8791}}, keywords = {{Graft-versus-host disease; Gut GVHD; Integrin; Stem cell transplant; Steroid refractory; Vedolizumab}}, language = {{eng}}, month = {{01}}, number = {{1}}, pages = {{172--175}}, publisher = {{Elsevier}}, series = {{Biology of Blood and Marrow Transplantation}}, title = {{Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease}}, url = {{http://dx.doi.org/10.1016/j.bbmt.2016.10.009}}, doi = {{10.1016/j.bbmt.2016.10.009}}, volume = {{23}}, year = {{2017}}, }